The analysis also discusses the regulatory alternatives FDA considered in drafting the proposed rule.
The regulatory alternatives FDA considered in drafting the proposed rule are also discussed in the analysis.
The analysis does not discuss the regulatory alternatives FDA considered in drafting the proposed rule.